Autologous hepatoma cell and splenic B lymphocyte fusion tumor vaccine (Shanghai Cp Guojian Pharmaceutical)
自体肝癌细胞及脾B淋巴细胞融合瘤苗（上海中信国健药业）
Report date: 2022/01/14 13:23:58
Base Information
Drug NameAutologous hepatoma cell and splenic B lymphocyte fusion tumor vaccine (Shanghai Cp Guojian Pharmaceutical)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Active IndicationsN/A
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A